Search Results for “EC” – Page 217 – media

in-PHARMA JAPAN

Organiser：Reed Exhibitions Time：July 9 – July 11, 2025 address： 3-21-1 Ariake, Koto-ku, Tokyo 135-0063, Japan Exhibition hall：Tokyo Big Sight International Exhibition Center Product range: Pharmaceutical Raw Materials and Ingredients: Pharmaceutical raw materials, Active Pharmaceutical Ingredients (API), intermediates, additives, functional raw materials, natural extracts, fine chemicals, business outsourcing/contract manufacturing/OEM, formulations, various analytical services and analytical equipment, as well as other raw materials, related services, and technologies. Pharmaceutical Machinery and Equipment: Packaging equipment/materials, containers, material processing equipment, sterilization and cleanroom equipment, process inspection/testing equipment, laboratory measurement/analysis equipment, pure water production/control equipment, supply and conveyor equipment, equipment engineering, pumps and valves, IT solutions, logistics services, etc. Biopharmaceuticals: Laboratory equipment/reagents, biologics, drug discovery, biotechnology, genomics, etc. About in-PHARMA JAPAN： in-PHARMA JAPAN is Japan’s leading B2B trade exhibition for pharmaceutical raw materials and ingredients. It attracts a large number of domestic and international pharmaceutical companies to visit, inspect, and actively engage in material selection ...
- Source: drugdu
- 104
- July 31, 2024
FDA Approves Alpha Cognition’s Zunveyl as Oral Therapy for Mild-to-Moderate Alzheimer Disease

July 29, 2024 By Don Tracy, Associate Editor Approval of Zunveyl offers a novel approach with a dual mechanism of action designed to improve tolerability and efficacy in treating Alzheimer disease, company says.The FDA has approved Alpha Cognition’s Zunveyl (benzgalantamine), an oral therapy for treating mild-to-moderate Alzheimer disease (AD). According to the company, the approval marks a significant advancement in the treatment of AD by offering a novel approach with a dual mechanism of action designed to improve tolerability and efficacy. Zunveyl is a prodrug of galantamine, an acetylcholinesterase inhibitor (AChEI), that works by preventing the breakdown of acetylcholine, a crucial neurotransmitter involved in memory and attention. Alpha Cognition stated that Zunveyl functions as an allosteric potentiator, enhancing the release of acetylcholine from presynaptic neurons.1 “I am very excited about the approval of Zunveyl, which we believe offers better tolerability for patients with Alzheimer’s disease. We have always believed in ...
- Source: drugdu
- 82
- July 31, 2024
GSK, Flagship Pioneering Commit $150M to Start R&D Pact for Novel Drugs and Vaccines

Respiratory disease and immunology are the initial focus areas of GSK’s new drug discovery partnership with Flagship Pioneering. A similar Flagship alliance with Pfizer recently announced it is pursuing novel obesity treatments. By Frank VinluanGSK already has a strong presence in respiratory disease and immunology, two of its core therapeutic areas. The pharmaceutical giant is now teaming up with Flagship Pioneering in an alliance intended to discover novel medicines to bolster its pipelines in both disease categories. The deal announced Monday calls for the partners to fund up to $150 million up front for an exploration phase intended to identify concepts that can leverage the technologies of Flagship’s portfolio companies. Flagship forms and incubates startups, each one based on a platform technology that focuses on some aspect of biology. The research stemming from these platforms informs the discovery and development of novel medicines. The best known of these “bioplatform” companies ...
- Source: drugdu
- 101
- July 31, 2024
Dexcom shares plunge on lower sales outlook

Dexcom lowered its sales forecast for 2024, surprising Wall Street as it lost market share among durable medical equipment (DME) providers and restructured its salesforce. Shares of the company were down 41% Friday morning. The diabetes device firm now expects 2024 revenue of $4 billion to $4.05 billion, a decrease from its previous forecast of $4.2 billion to $4.35 billion. “We have higher expectations for our business than what we experienced this quarter,” CEO Kevin Sayer told investors on Thursday, adding that he expects “more from myself and more from my team going forward.” Sayer attributed the lower sales outlook to three factors: a salesforce restructuring, lower revenue per customer due to rebates, and a loss of market share in the durable medical equipment channel. Those dynamics put Dexcom’s U.S. revenue about $40 million below the company’s internal estimates, CFO Jereme Sylvain said. The company also had about 70,000 fewer ...
- Source: drugdu
- 77
- July 30, 2024
New study examines educational disruptions for children

Children with special health care needs (CSHCN) often face significant disruptions in their education due to extended hospitalizations. A recent study published online in Disability and Rehabilitation on July 1, 2024, by a multidisciplinary team of Kessler Foundation and Children Specialized Hospital researchers, highlights critical areas needing attention to ensure smoother school re-entries for CSHCN, ensuring they receive the necessary educational support post-hospitalization. Involving parents, former patients, and rehabilitation professionals, the study underscores the need for better coordination and communication to facilitate seamless transitions back to school for CSHCN. Titled Experiences of patients, parents, and healthcare professionals in the process of transitioning from hospital to community after inpatient pediatric rehabilitation among children with special health care needs (https://doi.org/10.1080/09638288.2024.2362951), the article offers insights into the challenges and solutions for improving school re-entry for CSHCN. Foundation authors are Yu-Lun Chen, PhD, OTR/L; Stephanie Jimenez; Alexa Bartalotta; John O’Neill, PhD; and Amanda L. ...
- Source: drugdu
- 65
- July 30, 2024
Study suggests targeting amyloid beta production could be promising in AD

A study led by the UK Dementia Research Institute (UK DRI) and University College London (UCL) has suggested targeting amyloid beta production in one cell type in the brain could improve early disease outcomes, with fewer side effects, in Alzheimer’s disease (AD). Published in the journal PLOS Biology, findings suggest that targeting the production of amyloid beta specifically from oligodendrocytes could be a promising therapeutic strategy for treating the neurodegenerative condition. Currently the most common cause of dementia, AD is a progressive, neurodegenerative disease that causes the brain to shrink and brain cells to die. Accumulation of misfolded amyloid beta is recognised as one of the hallmarks of AD, which is believed to be caused by neurons. Researchers aim to test whether oligodendrocytes, a neural cell that produces myelin, the insulating material that surrounds the projections that transfer impulses between neurons, called axons, could produce harmful amyloid beta and whether ...
- Source: drugdu
- 69
- July 30, 2024
KCL study finds cell ageing could reveal early signs of neurodegenerative disease

Researchers from King’s College London (KCL), along with other collaborators, have found that ageing cells could reveal early signs of neurodegenerative diseases, including Alzheimer’s disease or amyotrophic lateral sclerosis. Published in Aging Cell, the findings could provide a wider picture of a target area for drugs and could improve treatments for these types of conditions. Affecting more than one million people in the UK, neurodegenerative conditions, such as multiple sclerosis and Parkinson’s disease, occur when cells of the central nervous system stop working or die. Using fluorescence to measure the viscosity of neuronal cytoplasm, the fluid enclosed by the cell membrane of the neuron, in mice, researchers found that the viscosity of the cytoplasm in the neuron (soma) increased as the mice aged. However, it did not increase in the cytoplasm of the axon, a tail-like structure that transmits electrical and chemical signals to other cells. Researchers suggested that the ...
- Source: drugdu
- 58
- July 30, 2024
Ractigen Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy

SUZHOU, China, July 25, 2024 /PRNewswire/ — Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to RAG-18, one of the company’s lead saRNA product candidates for the treatment of Duchenne Muscular Dystrophy (DMD). RAG-18 could represent a novel and translatable therapeutic strategy for DMD and Becker Muscular Dystrophy (BMD) caused by any mutation of the DMD gene. The RPDD is granted by the FDA to drugs that treat serious or life-threatening diseases primarily affecting children under 18 years of age with a prevalence of fewer than 200,000 in the United States. If a New Drug Application (NDA) for RAG-18 is approved, Ractigen may be eligible to receive a Priority Review Voucher (PRV), which can be used to expedite the review of a subsequent marketing application for a different product or ...
- Source: drugdu
- 87
- July 30, 2024
study

Dive Brief A recent study showed that a version of ChatGPT analyzes medical images at an expert level but frequently reached the right answer with incorrect reasoning. The results, which were published Tuesday in the peer-reviewed journal npj Digital Medicine, show OpenAI’s artificial intelligence GPT-4 with vision is as good at answering multiple-choice questions about medical images as physicians who lack access to external resources. However, the model made mistakes in image comprehension, while still reaching the right answer, 27% of the time. The researchers said the errors show the need for further study before the AI models are integrated into clinical workflows. Dive Insigh GPT-4 with vision, called GPT-4V, is a version of the ChatGPT large language model that can analyze images and text at the same time. Pilot medical studies found the model outperformed medical students and physicians in closed-book settings. However, those studies looked at the answers ...
- Source: drugdu
- 76
- July 29, 2024
Integrity Partners With Gosen Insurance Group to Bring New Solutions to Hispanic Communities in Florida

By Mike Hollan The partnership will allow both group to expand their operations and provide more solutions to underserved communities. Integrity Marketing Group and Gosen Insurance Group are partnering to provide more benefit to underserved markets.1 Gosen is an independent insurance company located in Kissimmee, Florida, that focuses on providing Medicare solutions to the Hispanic community in the area. One of the company’s strengths is its ability to provide education of Medicare and coverage options in the native language of many of the community members. In a press release, Integrity CEO and co-founder Bryan W. Adams said, “Katiry and Alex embody a strong spirit of empathy, compassion, and service. They are true servant-leaders within the Hispanic community and bring a deep commitment to improve the lives of the clients and agents they serve. With Integrity’s world-class resources and groundbreaking technology alongside them, Katiry and Alex can support their diverse community ...
- Source: drugdu
- 87
- July 29, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.